Joincare Pharmaceutical Group Industry Co., Ltd. Class ASSE: 600380

Indicative Announcement on Inclusion of Rekonkitta Monoclonal Antibody Injection into the Priority Review and Approval Program

· Issued by Joincare Pharmaceutical Group Industry Co., Ltd. Class A via Shanghai Stock Exchange
Indicative Announcement on Inclusion of Rekonkitta Monoclonal Antibody Injection into the Priority Review and Approval Program

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment